Published in final edited form as:

Mol Cancer Res. 2018 September ; 16(9): 1443. doi:10.1158/1541-7786.MCR-18-0818.

Retraction: Embelin Suppresses Osteoclastogenesis Induced by Receptor Activator of NF- κ B Ligand and Tumor Cells *In vitro* through Inhibition of the NF- κ B Cell Signaling Pathway

This article (1) has been retracted at the request of the editors. An institutional investigation determined that the same microscopy image was used to represent different experimental conditions (3- and 4-day embelin treatments) in Fig. 2A. Original research records related to this concern were not available during the institutional investigation. In addition, an internal journal investigation determined that the cleaved caspase-3 band in the combined 10 mmol/L embelin and 5 nmol/L RANKL treatment appears to have been digitally inserted into the immunoblot in Fig. 5E.

A copy of this Retraction Notice was sent to the last known email addresses for all six authors. Two authors (S. Reuter and K. Phromnoi) did not agree to the retraction; the four remaining authors (S. Prasad, R. Kannappan, V.R. Yadav, and B.B. Aggarwal) did not respond.

Reference

1. Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB. Embelin suppresses osteoclastogenesis induced by receptor activator of NF- κ B ligand and tumor cells in vitro through inhibition of the NF- κ B cell signaling pathway. *Mol Cancer Res* 2010;8:1425–36. [PubMed: 20826545]